FDA Issues Final Guidance on Pathway for Interchangeable Biologics – Drug for nerve pain boosts high for opioid abusers.

16321_pharmacyboard_standard_080416Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Issues Final Guidance on Pathway for Interchangeable Biologics – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

In an effort to promote competition in the biologic market, officials with the FDA today released a final guidance on the pathway for interchangeable biosimilar products.

According to a statement released by acting FDA Commissioner Ned Sharpless, MD, the final guidance will provide clarity for developers who want to demonstrate that their proposed biological products meet the statutory interchangeability standard under the Public Health Service Act. Ultimately, the goal is to help patients by making more treatment options available.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.